Alan S. Coates
0000-0002-0141-7356
Publication & Citation Trends
Publications
413 total
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials
Cited by 3
Semantic Scholar
The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.
Cited by 0
Semantic Scholar
Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT
Cited by 0
Semantic Scholar
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT OA
Cited by 65
Semantic Scholar
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. OA
Cited by 23
Semantic Scholar
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 PDF
Cited by 1,829
OpenAlex
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. OA
Cited by 7
Semantic Scholar
Reply to: prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer. OA
Cited by 1
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(195)
Estrogen and related hormone effects
(111)
Cancer Treatment and Pharmacology
(58)
HER2/EGFR in Cancer Research
(56)
Advanced Breast Cancer Therapies
(56)
Affiliations
Roche (Switzerland)
University of Bern
Leiden University
Betsi Cadwaladr University Health Board
Roswell Park Comprehensive Cancer Center